Abstract: A marine propulsion system for a marine vessel includes one steerable rear marine drive positioned along the center line of the marine vessel and a lateral marine drive positioned at a bow region of the marine vessel. The rear marine drive is steerable about a vertical steering axis to a range of steering angles. The lateral marine drive is positioned at a fixed angle with respect to the marine vessel and configured to generate lateral thrust on the marine vessel. A user input device is operable by a user to provide a propulsion demand input commanding surge movement, sway movement, and yaw movement of the marine vessel, and the control system is configured to control steering and thrust of the rear marine drive and thrust of the lateral marine drive based on the propulsion demand input to generate the surge movement, sway movement, and/or the yaw movement commanded by the user.

Abstract: Various aspects of a generator, ultrasonic device, and method for estimating a state of an end effector of an ultrasonic device are disclosed. The ultrasonic device includes an electromechanical ultrasonic system defined by a predetermined resonant frequency, including an ultrasonic transducer coupled to an ultrasonic blade. A control circuit measures a complex impedance of an ultrasonic transducer, wherein the complex impedance is defined as Zg(t)=Vg(t)/Ig(t). The control circuit receives a complex impedance measurement data point and compares the complex impedance measurement data point to a data point in a reference complex impedance characteristic pattern. The control circuit then classifies the complex impedance measurement data point based on a result of the comparison analysis and assigns a state or condition of the end effector based on the result of the comparison analysis.

Abstract: The present invention features methods for selecting treatment for a patient having suffered a minor stroke or transient ischemic attack (TIA) associated with intracranial atherosclerotic disease (ICAD).

Abstract: A surgical instrument, has an end effector that includes an ultrasonic blade, and a clamp arm that moves relative to the ultrasonic blade from an opened position toward an intermediate position and a closed position. The clamp arm is offset from the ultrasonic blade to define a predetermined gap in the intermediate position between the opened position and the closed position. A clamp arm actuator connects to the clamp arm and moves from an opened configuration to a closed configuration to direct the clamp arm from the opened position toward the intermediate position and the closed position. A spacer connects with the clamp arm to inhibit movement of the clamp arm from the intermediate position toward the closed position for maintaining the predetermined gap between the clamp arm and the ultrasonic blade.

Abstract: Bone implants, including methods of use and assembly. The bone implants, which are optionally composite implants, generally include a distal anchoring region and a growth region that is proximal to the distal anchoring region. The distal anchoring region can have one or more distal surface features that adapt the distal anchoring region for anchoring into iliac bone. The growth region can have one or more growth features that adapt the growth region to facilitate at least one of bony on-growth, in-growth, or through-growth. The implants may be positioned along a posterior sacral alar-iliac (“SAI”) trajectory. The implants may be coupled to one or more bone stabilizing constructs, such as rod elements thereof.

Abstract: A powered fastener driver includes a driver blade movable from a top-dead-center position to a bottom-dead-center position for driving a fastener into a workpiece, a drive unit for providing torque to move the driver blade toward the top-dead-center position, and a rotary lifter engageable with the driver blade. The lifter having a body and a drive pin coupled to the body. A roller is positioned on the drive pin and engages with a tooth of the driver blade when moving the driver blade from the bottom-dead-center position toward the top-dead-center position. The roller includes a first engagement section that receives an end portion of the tooth and a second engagement section. An engagement member engages the second engagement section for aligning the first engagement section of the roller with the end portion of the tooth to facilitate meshing between the end portion of the tooth and the roller.

Abstract: Various aspects of a generator, ultrasonic device, and method for estimating a state of an end effector of an ultrasonic device are disclosed. The ultrasonic device includes an electromechanical ultrasonic system defined by a predetermined resonant frequency, including an ultrasonic transducer coupled to an ultrasonic blade. A control circuit measures a complex impedance of an ultrasonic transducer, wherein the complex impedance is defined as Z g ( t ) = V g ( t ) I g ( t ) . The control circuit receives a complex impedance measurement data point and compares the complex impedance measurement data point to a data point in a reference complex impedance characteristic pattern. The control circuit then classifies the complex impedance measurement data point based on a result of the comparison analysis and assigns a state or condition of the end effector based on the result of the comparison analysis.

Abstract: Antimicrobial compositions used to form a residual dry-coat include a halo active aromatic sulfonamide compound of Formula (I): wherein the variables R1, R2, R3, R4, R5, X, M and n are disclosed herein. The compositions and processes utilizing the same can be used as a dry coating or layer to maintain disinfected surfaces with reduced microbial count over extended time periods ranging from multiple days up to several weeks.

Abstract: Disclosed herein are compositions useful for the treatment and/or prevention of various diseases and conditions, including a variety of infections, via internal administration to a patient. The compositions comprise an effective amount of a halo active aromatic sulfonamide compound having the structure of Formula (I): wherein R1, R2, R3, R4, and R5, X, and M are defined herein. The compositions described may be used to treat and/or prevent a variety of infections, including bacterial infections, viral infections, fungal infections, and the like. The compositions can be internally administered to a patient via at least one of: oral administration, pulmonary administration, subcutaneous administration, sublingual administration, ocular administration, otic administration, intravenous administration, inter-dermal administration, epidural administration, intraperitoneal administration, and intramuscular administration.

Abstract: Disclosed herein are compositions useful for the treatment and/or prevention of various skin conditions, including infections, via external and/or topical administration to a patient. The compositions comprise an effective amount of a halo active aromatic sulfonamide compound having the structure of Formula (I): wherein R1, R2, R3, R4, and R5, X, and M are defined herein. The compositions described may be used to treat and/or prevent a variety of skin conditions, including acne, eczema, rosacea, hives, psoriasis, athlete's foot, candidiasis, shingles, chicken pox, cold sores, bacterial infections, viral infections, fungal infections, and the like. The compositions can be externally and/or topically administered to a patient, for example, as a spray or a wipe. Further, the compositions can also be externally and/or topically administered to a patient by, for example, applying the composition to a medical device that is then implanted into the patient or contacted with the patient.

Abstract: Articles are treated with a reduced amount of a halo active aromatic sulfanomide compound of Formula (I): wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, COOR?, CON(R?)2, alkoxy, CN, NO2, SO3R?, halogen, substituted or unsubstituted phenyl, sulfonamide, halosulfonamide, and substituted or unsubstituted C1-C12 alkyl; R? is hydrogen, an alkali metal, an alkaline earth metal, substituted C1-C12 alkyl, or unsubstituted C1-C12 alkyl; and R? is hydrogen or substituted or unsubstituted C1-C12 alkyl, where the two R? groups in CON(R?)2 may be independently selected; X is halogen; M is an alkali or alkaline earth metal; and n is the number of water molecules per molecule of the sulfonamide compound. The compound effectively suppresses odors pre-use, in use, and post-use for extended periods of time.

Abstract: Antimicrobial compositions used to form a residual dry-coat include a halo active aromatic sulfonamide compound of Formula (I): wherein the variables R1, R2, R3, R4, R5, X, M and n are disclosed herein. The compositions and processes utilizing the same can be used as a dry coating or layer to maintain disinfected surfaces with reduced microbial count over extended time periods ranging from multiple days up to several weeks.

Abstract: A filter is treated with a reduced amount of a halo active aromatic sulfanomide compound of Formula (I): wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, COOR?, CON(R?)2, alkoxy, CN, NO2, SO3R?, halogen, substituted or unsubstituted phenyl, sulfonamide, halosulfonamide, and substituted or unsubstituted C1-C12 alkyl; R? is hydrogen, an alkali metal, an alkaline earth metal, substituted C1-C12 alkyl, or unsubstituted C1-C12 alkyl; and R? is hydrogen or substituted or unsubstituted C1-C12 alkyl, where the two R? groups in CON(R?)2 may be independently selected; X is halogen; M is an alkali or alkaline earth metal; and n is the number of water molecules per molecule of the sulfonamide compound. The compound effectively suppresses odors pre-use, in use, and post-use for extended periods of time.

Abstract: Articles are treated with a reduced amount of a halo active aromatic sulfanomide compound of Formula (I): wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, COOR?, CON(R?)2, alkoxy, CN, NO2, SO3R?, halogen, substituted or unsubstituted phenyl, sulfonamide, halosulfonamide, and substituted or unsubstituted C1-C12 alkyl; R? is hydrogen, an alkali metal, an alkaline earth metal, substituted C1-C12 alkyl, or unsubstituted C1-C12 alkyl; and R? is hydrogen or substituted or unsubstituted C1-C12 alkyl, where the two R? groups in CON(R?)2 may be independently selected; X is halogen; M is an alkali or alkaline earth metal; and n is the number of water molecules per molecule of the sulfonamide compound. The compound effectively suppresses odors pre-use, in use, and post-use for extended periods of time.

Abstract: Processes for extracting iodine from an aqueous solution, such as brine, are disclosed. Activated coconut carbon particles are mixed with the solution to adsorb iodide through pores in the activated carbon particles. The activated carbon particles are then treated with sulfur dioxide gas and water to form hydrogen iodide. The hydrogen iodide is then reacted with chloride to obtain elemental iodine (I2).

Abstract: Articles are treated with a reduced amount of a halo active aromatic sulfonamide compound of Formula (I): wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, COOR?, CON(R?)2, alkoxy, CN, NO2, SO3R?, halogen, substituted or unsubstituted phenyl, sulfonamide, halosulfonamide, and substituted or unsubstituted C1-C12 alkyl; R? is hydrogen, an alkali metal, an alkaline earth metal, substituted C1-C12 alkyl, or unsubstituted C1-C12 alkyl; and R? is hydrogen or substituted or unsubstituted C1-C12 alkyl, where the two R? groups in CON(R?)2 may be independently selected; X is halogen; M is an alkali or alkaline earth metal; and n is the number of water molecules per molecule of the sulfonamide compound. The compound effectively suppresses odors pre-use, in use, and post-use for extended periods of time.

Abstract: A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of between about 25 ?g/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 ?g/kg/min, wherein the active drug is tirofiban or a salt thereof.

Abstract: A filter is treated with a reduced amount of a halo active aromatic sulfanomide compound of Formula (I): wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, COOR?, CON(R?)2, alkoxy, CN, NO2, SO3R?, halogen, substituted or unsubstituted phenyl, sulfonamide, halosulfonamide, and substituted or unsubstituted C1-C12 alkyl; R? is hydrogen, an alkali metal, an alkaline earth metal, substituted C1-C12 alkyl, or unsubstituted C1-C12 alkyl; and R? is hydrogen or substituted or unsubstituted C1-C12 alkyl, where the two R? groups in CON(R?)2 may be independently selected; X is halogen; M is an alkali or alkaline earth metal; and n is the number of water molecules per molecule of the sulfonamide compound. The compound effectively suppresses odors pre-use, in use, and post-use for extended periods of time.

Abstract: A system and method for soft tissue repair. According to one embodiment, sensing gauges or other sensing technologies are utilized at distal ends of jaws, passing a needle or within the instrument to identify tissue differences that give the end user feedback on these differences. A console connected to the instrument assists in utilizing sensing technology to give the end user feedback on tissue differences.

Abstract: An odor-controlling bodily fluid absorbent member comprises (a) an absorbent material or substrate; and (b) a halo active aromatic sulfonamide compound of Formula (I): wherein R1, R2, R3, R4, R5, X, M, and n are as described herein; and wherein at least one of R1, R2, R3, R4, and R5 is not hydrogen. The absorbent member effectively controls odor arising from various body fluids.